Bevacizumab, Lonsurf, Taiho Oncology, tipiracil, Trifluridine
Trifluridine and tipiracil with bevacizumab is approved by FDA for previously treated metastatic colorectal cancer
August 2023: For metastatic colorectal cancer (mCRC) that has already been treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy..
futibatinib, Lytgobi, NCT02052778, Taiho Oncology, TAS-120-101
Cccelerated approval is granted by FDA to futibatinib for cholangiocarcinoma
November 2022: The Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic chol..